Product Overview
[Drug Name]
Generic Name: Isosorbide Mononitrate Sustained-Release Tablets
Trade Name: Yimuduo
English Name: Isosorbide Mononitrate Sustained-Release Tablets
Chinese Pinyin: Danxiaosuan Yishanlizhi Huanshi Pian
[Ingredients]
Isosorbide mononitrate, chemical name: 1,4;3,6-dianhydro-D-sorbitol-5-nitrate.
[Appearance]
Film-coated tablets, white or off-white after removal of the coating.
[Indications]
Long-term treatment of coronary heart disease, prevention of vasospastic and mixed angina, also suitable for post-myocardial infarction treatment and long-term treatment of chronic heart failure.
[Dosage and Administration]
Oral: Take one tablet daily in the morning. For severe cases, take two tablets daily in the morning. If headaches occur, the initial dose can be reduced to half a tablet daily. The whole or half tablet should be kept intact before taking and swallowed with half a glass of water. Do not chew or crush.
[Adverse Reactions]
Headache may occur at the beginning of treatment, but symptoms disappear with continued use. Occasionally, symptoms such as hypotension, drowsiness, and nausea may occur, but these symptoms generally disappear with continued use.
[Contraindications]
This product is contraindicated in patients with glaucoma, shock, significant hypotension, hypertrophic obstructive heart disease, acute myocardial infarction, or severe cerebral arteriosclerosis.
[Precautions]
1. Use with caution in patients with acute myocardial infarction and low ventricular filling pressure.
2. Use with caution in patients with postural circulatory disturbances.
3. Not for use in acute angina attacks.
[Use in Special Populations]
Precautions for Children:
The safety and efficacy of this product in children have not been established.
Precautions for Pregnancy and Lactation:
Use with caution in pregnant and lactating women.
Precautions for the Elderly:
Elderly patients may be more sensitive to this drug class and may be more susceptible to reactions such as dizziness.
[Drug Interactions]
Not yet known.
[Pharmacological Actions]
Isosorbide mononitrate is the primary active metabolite of isosorbide dinitrate. It may reduce myocardial oxygen consumption by dilating peripheral blood vessels, particularly increasing venous blood volume, reducing venous return, and lowering cardiac preload and postload. It may also improve blood flow to the ischemic area by promoting myocardial blood flow redistribution, potentially exerting its anti-ischemic effects through these two mechanisms.
[Storage]
Store in a sealed container away from light.
[Specification]
60mg x 7 tablets
[Packaging]
Box
[Expiration Date]
36 months
[Approval Number]
National Medicine Approval No. H20030418
[Manufacturer]
Company Name: AstraZeneca Pharmaceuticals Co., Ltd.
